Karyopharm Therapeutics (KPTI) Competitor Comparison
We are evaluating the key criteria listed to compare Karyopharm Therapeutics (KPTI) against its competitors in the Biotechnology industry.
Market Capitalization
238 / 368Gross Profits
39 / 278Total Revenue
75 / 300EBITDA
220 / 337Free Cashflow
198 / 352Quick Ratio
220 / 357Earnings per Share
153 / 359Dividend yield
0 / 6Total Cash
152 / 358Performance 3 years
309 / 368Performance 5 years
267 / 368Performance 10 years
310 / 368Linearity 3 years
225 / 368Linearity 5 years
100 / 368Linearity 10 years
214 / 368Total Rank
173 / 368Dividend Rank
179 / 368Valuation Rank
147 / 368Piotroski Rank
223 / 368Muliplier Rank
45 / 368Dividend yield - KPTI ranking 0 / 6
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.